Michel Michaelides, MD, discusses phase 3 DRAGON results showing that oral tinlarebant slowed atrophic lesion growth by about 36% in adolescents with Stargardt disease.
Michel Michaelides, MD, FRCOphth
Advertisement
Michaelides is professor at UCL Institute of Ophthalmology and Moorfields Eye Hospital, London.
E: michel.michaelides@ucl.ac.uk
Articles by Michel Michaelides, MD, FRCOphth
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
2
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
3
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
4
Think outside the cone: The Gulani keratoconus classification
5